Veracyte (VCYT) Competitors $31.05 -2.64 (-7.84%) Closing price 03/26/2025 04:00 PM EasternExtended Trading$31.13 +0.08 (+0.26%) As of 03/26/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VCYT vs. HIMS, OPCH, GH, RDNT, SHC, SGRY, BTSG, PRVA, CON, and WGSShould you be buying Veracyte stock or one of its competitors? The main competitors of Veracyte include Hims & Hers Health (HIMS), Option Care Health (OPCH), Guardant Health (GH), RadNet (RDNT), Sotera Health (SHC), Surgery Partners (SGRY), BrightSpring Health Services (BTSG), Privia Health Group (PRVA), Concentra Group Holdings Parent (CON), and GeneDx (WGS). These companies are all part of the "healthcare" industry. Veracyte vs. Hims & Hers Health Option Care Health Guardant Health RadNet Sotera Health Surgery Partners BrightSpring Health Services Privia Health Group Concentra Group Holdings Parent GeneDx Hims & Hers Health (NYSE:HIMS) and Veracyte (NASDAQ:VCYT) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk, earnings and community ranking. Do analysts rate HIMS or VCYT? Hims & Hers Health presently has a consensus target price of $37.31, indicating a potential upside of 11.72%. Veracyte has a consensus target price of $43.40, indicating a potential upside of 39.77%. Given Veracyte's stronger consensus rating and higher possible upside, analysts plainly believe Veracyte is more favorable than Hims & Hers Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hims & Hers Health 2 Sell rating(s) 7 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.27Veracyte 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70 Which has stronger earnings and valuation, HIMS or VCYT? Hims & Hers Health has higher revenue and earnings than Veracyte. Hims & Hers Health is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHims & Hers Health$1.48B5.02-$23.55M$0.5461.84Veracyte$445.76M5.43-$74.40M$0.30103.50 Does the media prefer HIMS or VCYT? In the previous week, Hims & Hers Health had 8 more articles in the media than Veracyte. MarketBeat recorded 26 mentions for Hims & Hers Health and 18 mentions for Veracyte. Hims & Hers Health's average media sentiment score of 1.08 beat Veracyte's score of 0.96 indicating that Hims & Hers Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hims & Hers Health 18 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Veracyte 8 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is HIMS or VCYT more profitable? Hims & Hers Health has a net margin of 8.19% compared to Veracyte's net margin of -2.18%. Hims & Hers Health's return on equity of 10.97% beat Veracyte's return on equity.Company Net Margins Return on Equity Return on Assets Hims & Hers Health8.19% 10.97% 8.29% Veracyte -2.18%3.02%2.80% Does the MarketBeat Community favor HIMS or VCYT? Veracyte received 406 more outperform votes than Hims & Hers Health when rated by MarketBeat users. Likewise, 73.01% of users gave Veracyte an outperform vote while only 37.07% of users gave Hims & Hers Health an outperform vote. CompanyUnderperformOutperformHims & Hers HealthOutperform Votes4337.07% Underperform Votes7362.93% VeracyteOutperform Votes44973.01% Underperform Votes16626.99% Which has more risk and volatility, HIMS or VCYT? Hims & Hers Health has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500. Comparatively, Veracyte has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500. Do insiders & institutionals have more ownership in HIMS or VCYT? 63.5% of Hims & Hers Health shares are held by institutional investors. 17.7% of Hims & Hers Health shares are held by insiders. Comparatively, 1.3% of Veracyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryHims & Hers Health beats Veracyte on 11 of the 18 factors compared between the two stocks. Remove Ads Get Veracyte News Delivered to You Automatically Sign up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VCYT vs. The Competition Export to ExcelMetricVeracyteMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.42B$2.89B$5.62B$8.13BDividend YieldN/A21.70%4.56%4.00%P/E Ratio-207.0013.2424.5319.09Price / Sales5.43201.14385.7894.71Price / Cash442.2957.5638.1634.64Price / Book2.174.586.934.36Net Income-$74.40M-$22.21M$3.20B$247.23M7 Day Performance-2.48%-1.66%-2.20%-0.34%1 Month Performance-8.24%-2.50%3.13%-3.60%1 Year Performance42.96%0.93%10.99%2.01% Veracyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VCYTVeracyte4.5691 of 5 stars$31.05-7.8%$43.40+39.8%+46.7%$2.42B$445.76M-207.00790Analyst ForecastHIMSHims & Hers Health3.2728 of 5 stars$34.68+4.6%$37.23+7.4%+111.2%$7.70B$1.48B78.821,046Positive NewsOPCHOption Care Health3.9556 of 5 stars$33.89+3.8%$33.00-2.6%+6.6%$5.60B$5.00B28.485,600Positive NewsGHGuardant Health3.7107 of 5 stars$42.90+0.0%$48.40+12.8%+159.1%$5.29B$739.02M-12.051,790Analyst ForecastNews CoverageRDNTRadNet3.8633 of 5 stars$49.02+5.3%$76.75+56.6%+5.0%$3.63B$1.83B-700.198,970Analyst ForecastHigh Trading VolumeSHCSotera Health2.8528 of 5 stars$11.93+2.9%$15.92+33.4%+1.4%$3.38B$1.10B47.723,000Positive NewsSGRYSurgery Partners2.3252 of 5 stars$24.40+3.4%$36.63+50.1%-17.7%$3.11B$3.11B-50.8313,500Analyst ForecastBTSGBrightSpring Health Services2.548 of 5 stars$17.45+0.2%$21.67+24.2%+87.3%$3.05B$11.27B-67.1235,000PRVAPrivia Health Group3.6513 of 5 stars$23.24-2.1%$26.67+14.7%+20.6%$2.80B$1.74B232.421,102Positive NewsCONConcentra Group Holdings ParentN/A$21.04+1.2%$28.38+34.8%N/A$2.68B$1.90B13.9411,000Positive NewsWGSGeneDx2.3599 of 5 stars$94.46-4.1%$72.33-23.4%+1,003.4%$2.65B$305.45M-48.191,200Positive News Remove Ads Related Companies and Tools Related Companies Hims & Hers Health Competitors Option Care Health Competitors Guardant Health Competitors RadNet Competitors Sotera Health Competitors Surgery Partners Competitors BrightSpring Health Services Competitors Privia Health Group Competitors Concentra Group Holdings Parent Competitors GeneDx Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VCYT) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veracyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veracyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
